Loading stock data…
IRD
$5.14+0.03 (+0.59%)
Market ClosedLast close May 1
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Opus Genetics, Inc. in the Healthcare sector is trading at $5.14. The stock is currently near its 52-week high of $5.81, remaining 96.2% above its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why IRD maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.14
Potential Upside
5%
Whystock Fair Value$5.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It d...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$390.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-323.11%
Volume
Today's trading volume
592,717
Recent News
Citizens Initiates Coverage of Opus Genetics (IRD)
Opus Genetics, Inc. (NASDAQ:IRD) is one of the best performing small cap stocks so far in 2026. On April 28, Citizens initiated coverage of Opus Genetics, Inc. (NASDAQ:IRD) with an Outperform rating, setting a price target of $12. The firm told investors in a research note that the company is in the process of developing a […]
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating
Opus Genetics, Inc. (NASDAQ:IRD) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 2, 2026, BTIG raised the price target on Opus Genetics, Inc. (NASDAQ:IRD) to $12 from $7 and maintained a Buy rating. BTIG said the company’s investment story appears to be gaining momentum after the initial BEST1 correction […]
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -31.21% and +47.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of -75.51% and -94.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.7% and the S